Saturday 17 October 2026 Export HLN’s income statement to Excel — free account

Haleon PLC Sponsored ADR

HLN Healthcare Drug Manufacturers Specialty & Generic

Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024. Revenue growth for three consecutive years, operating cash flow growth for three.

10.13 0.19 +1.91%

Follow HLN

Alert me

Market cap: $43.7B
P/E: 22.6×
Fwd P/E: 17.6×
Dividend yield: 1.95%
F-score: 8/9
Altman Z: 3.04
Beneish M: −2.60
Dividend safety: 66/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 4.36%

Capital & Financial Ratios $m

Market Cap 43,710.00

Revenue 18,122.53

Net Income 3,070.88

Free Cash Flow 4,551.19

Net Debt 9,966.43

Current Ratio 0.69

Debt/Equity 0.50

P/E ratio 22.58

Fwd P/E 17.60

P/S ratio 2.57

P/B ratio 2.11

Past 5Y EPS Growth 24.41%

This Y EPS Growth 10.32%

Next Y EPS Growth 8.86%

Next Y revenue growth 3.03%

Next 5Y EPS Growth 9.04%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/B against its own 10 years 69.66%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 0.20

Annual Dividend Yield 1.95%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	0.11	0.13 0.06
2025	0.10	0.12 0.06
2024	0.16	0.11 0.05
2023	0.10	0.06 0.04

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,299	2,875	1,746	1,109
Receivables	2,422	2,745	2,800	3,151
Inventory	1,751	1,521	1,352	1,437
Other	521	166	103	62
	5,993	7,307	6,000	5,759

	2023	2024	2025	Q'26
Payables	4,386	4,735	4,919	5,095
ST’ Debt	816	1,900	1,102	2,633
Other	211	492	132	297
	5,772	7,427	6,505	8,380

Compound Annual Growth %

	10y	5y	3y
Sales	—	1.43%	2.69%
Cash Flow	—	12.50%	10.83%
Earnings	—	6.98%	18.80%
Book Value	—	(9.48%)	2.21%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	14,545
’24	3,702	—	3,616	—	14,355
’23	3,627	7,263	3,542	—	14,059
’22	—	—	—	—	13,430
’21	—	—	—	—	12,899
’20	—	—	—	—	13,551

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	3,473
’24	—	—	—	—	2,940
’23	—	—	—	—	2,612
’22	—	—	—	—	2,552
’21	—	—	—	—	1,834
’20	—	—	—	—	1,927

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	1,241	—	—	—
’25	—	1,199	—	—	2,929
’24	—	1,339	—	—	2,949
’23	—	771	—	—	2,500
’22	—	757	—	2,176	2,191
’21	—	—	—	—	1,834
’20	—	—	—	—	1,927

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	0.49
’24	0.12	—	0.14	—	0.40
’23	0.10	0.09	0.10	—	0.28
’22	—	—	—	—	0.28
’21	—	—	—	—	0.20
’20	—	—	—	—	0.16

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	5.59	7.49	7.89	8.71	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	8.50	9.05	10.80	11.42
People
People	Employees	—	—	—	—	—	22,800	24,622	25,408	24,561	24,535
	Revenue/emp, $m	—	—	—	0.00	0.00	0.57	0.55	0.55	0.58	0.59
Income, $m
Income, $m	Revenue	—	—	—	11,158	13,551	12,899	13,430	14,059	14,355	14,545
	Gross margin, %	—	—	—	56.63	59.75	62.34	60.57	59.70	60.75	64.19
	EBT	—	—	—	1,166	2,179	2,211	2,001	2,025	2,441	2,838
	EBT margin, %	—	—	—	10.45	16.08	17.14	14.90	14.40	17.00	19.51
	Net income	—	—	—	862	1,568	0	1,384	1,382	1,885	2,215
	Depreciation	—	—	—	342	418	362	355	384	414	475
Per share, $
Per share, $	Revenue	—	—	—	2.41	2.93	2.79	2.91	3.05	3.14	3.24
	Earnings	—	—	—	0.09	0.16	0.20	0.28	0.28	0.40	0.49
	Cash flow	—	—	—	0.22	0.42	0.40	0.55	0.57	0.64	0.77
	Capex	—	—	—	0.00	0.00	0.00	(0.08)	(0.02)	0.00	(0.12)
	Free cash flow	—	—	—	0.22	0.42	0.40	0.47	0.54	0.65	0.65
	Book value	—	—	—	7.78	7.74	7.71	4.41	4.51	4.54	4.84
	Shares, m	—	—	—	4,621	4,621	4,621	4,618	4,617	4,566	4,491
Valuation, ×
Valuation, ×	P/E	—	—	—	20.41	20.41	20.41	20.41	20.41	21.27	22.54
	P/S	—	—	—	0.00	0.00	0.00	0.00	0.00	2.42	2.57
	P/B	—	—	—	0.00	0.00	0.00	0.00	1.83	2.08	2.18
	EV/Sales	—	—	—	0.00	0.00	0.00	0.00	0.00	3.00	3.14
	EV/FCF	—	—	—	0.00	0.00	0.00	0.00	0.00	11.64	11.04
Cash, $m
Cash, $m	Operating cash flow	—	—	—	1,028	1,927	1,834	2,552	2,612	2,940	3,473
	Capex	—	—	—	(320)	(436)	(403)	(361)	(112)	9	(545)
	Free cash flow	—	—	—	1,028	1,927	1,834	2,191	2,500	2,949	2,929
Balance, $m
Balance, $m	Working capital	—	—	—	2,029	1,362	1,369	(385)	221	(120)	(505)
	Total debt	—	—	—	845	667	1,339	12,913	11,762	12,941	11,353
	Net debt	—	—	—	397	210	780	12,067	10,464	10,066	9,607
	Shareholders’ equity	—	—	—	35,949	35,770	35,615	20,356	20,809	20,733	21,737
Returns, %
Returns, %	ROA	—	—	—	0.00	3.35	8.04	2.92	3.06	4.27	5.06
	ROIC	—	—	—	0.00	0.00	0.00	4.35	4.96	5.72	6.34
	ROE	—	—	—	0.00	4.37	5.26	4.69	6.34	8.87	10.35

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TAK Takeda Pharmaceutical Co.	$61.9B	29.6×	—	+1.71% (above 0%: growing)	−4.35% (below 0%: shrinking)	−95.56% (below 0%: shrinking)	66.66%	16.51%	Compare
TEVA Teva Pharmaceutical Industries Ltd.	$47.9B	65.9×	30.7×	−0.81% (below 0%: shrinking)	n/m	+121.43% (above 0%: growing)	51.98%	(2.03%)	Compare
HLN Haleon PLC Sponsored ADR	$43.7B	22.6×	17.6×	−0.32% (below 0%: shrinking)	+40.00% (above 0%: growing)	−42.94% (below 0%: shrinking)	62.88%	25.36%
ZTS Zoetis Inc.	$32.4B	13.0×	12.3×	−0.24% (below 0%: shrinking)	+2.48% (above 0%: growing)	+17.43% (above 0%: growing)	72.73%	37.56%	Compare
UTHR United Therapeutics Corporation	$23.2B	17.6×	20.1×	−1.92% (below 0%: shrinking)	+13.99% (above 0%: growing)	+58.76% (above 0%: growing)	87.30%	42.23%	Compare
VTRS Viatris Inc.	$20.9B	— (loss-making)	61.1×	+4.88% (above 0%: growing)	n/m	+101.08% (above 0%: growing)	38.77%	0.17%	Compare
NBIX Neurocrine Biosciences, Inc.	$13.9B	19.2×	30.5×	+39.49% (above 0%: growing)	+31.19% (above 0%: growing)	+43.69% (above 0%: growing)	97.58%	15.80%	Compare
ELAN Elanco Animal Health Incorporated	$11.8B	— (loss-making)	278×	+10.23% (above 0%: growing)	+450.00% (above 0%: growing)	+35.56% (above 0%: growing)	58.33%	7.97%	Compare
RDY Dr. Reddy's Laboratories Ltd	$10.7B	32.9×	24.3×	−14.44% (below 0%: shrinking)	−70.00% (below 0%: shrinking)	−143.40% (below 0%: shrinking)	46.54%	4.81%	Compare
Median of peers	$22.1B	24.4×	30.5×	+0.74%	+8.23%	+39.63%	62.50%	11.89%

All 86 Drug Manufacturers Specialty & Generic stocks →

Haleon PLC Sponsored ADR (HLN) key facts

Strength: Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.
Haleon PLC Sponsored ADR (HLN) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, HLN traded at $10.13, a market capitalization of $43.7 billion.
Haleon PLC Sponsored ADR pays an annual dividend of $0.20 per share, a yield of 1.95%.
Return on equity was 10.4% and debt-to-equity 0.50.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 3.04 (safe zone) for fiscal 2025.